Microbion and Haisco Announce Equity Investment and Development & Commercialization Agreement for MBN-101 in China and Related Territories
Bozeman, MT and Vancouver, BC, March 1, 2016 – Microbion Corporation (“Microbion”) of Bozeman, MT, USA and Microbion Pharma Corp. of Vancouver, BC, Canada, today announced that Microbion has entered into an agreement with Haisco Pharmaceutical Group (“Haisco”) to develop and commercialize its lead clinical stage compound, MBN-101, for wounds in China and related territories. […]
Microbion Corporation is dedicated to safeguarding human health by overcoming infections, antibiotic resistance, and microbial biofilms with safe, effective anti-infective products.
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.
- Microbion filed an IND in the United States for MBN-101 in 2015.
The company initiated its first Phase 2a study directed at treatment of serious, life or limb threatening infections associated with orthopedic implants and chronic wounds in 2016.
- MBN-101 has been granted FDA Qualified Infectious Disease Product (QIDP) status for orthopedic device-related infections and was also granted Fast Track status for this indication in 2015 – – a designation that is anticipated to facilitate regulatory development and extend market exclusivity.
- Pre-clinical studies directed at the development of new antimicrobial/antibiofilm therapies for serious lung infections, systemic infections and for biodefense are underway or in the planning stages.